While Centessa Pharmaceuticals plc ADR has overperformed by 3.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CNTA rose by 2.51%, with highs and lows ranging from $19.09 to $9.10, whereas the simple moving average jumped by 13.29% in the last 200 days.
On July 21, 2025, Truist started tracking Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) recommending Buy. A report published by Needham on May 28, 2025, Initiated its previous ‘Buy’ rating for CNTA. Chardan Capital Markets also rated CNTA shares as ‘Buy’, setting a target price of $30 on the company’s shares in an initiating report dated May 08, 2025. Piper Sandler Initiated an Overweight rating on March 31, 2025, and assigned a price target of $38. TD Cowen initiated its ‘Buy’ rating for CNTA, as published in its report on January 07, 2025. Morgan Stanley’s report from September 20, 2024 suggests a price prediction of $26 for CNTA shares, giving the stock a ‘Overweight’ rating. B. Riley Securities also rated the stock as ‘Buy’.
Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
To gain a thorough understanding of Centessa Pharmaceuticals plc ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -74.29% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 14.37, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CNTA is recording an average volume of 992.60K. On a monthly basis, the volatility of the stock is set at 5.24%, whereas on a weekly basis, it is put at 6.87%, with a gain of 10.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $31.90, showing growth from the present price of $17.17, which can serve as yet another indication of whether CNTA is worth investing in or should be passed over.
How Do You Analyze Centessa Pharmaceuticals plc ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 36.00%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 57.02% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
